149 related articles for article (PubMed ID: 27282414)
1. Bladder tumor-targeted delivery of pro-apoptotic peptide for cancer therapy.
Jung HK; Kim S; Park RW; Park JY; Kim IS; Lee B
J Control Release; 2016 Aug; 235():259-267. PubMed ID: 27282414
[TBL] [Abstract][Full Text] [Related]
2. iRGD-targeted delivery of a pro-apoptotic peptide activated by cathepsin B inhibits tumor growth and metastasis in mice.
Qifan W; Fen N; Ying X; Xinwei F; Jun D; Ge Z
Tumour Biol; 2016 Aug; 37(8):10643-52. PubMed ID: 26867766
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of Tumor Growth against Chemoresistant Cholangiocarcinoma by a Proapoptotic Peptide Targeting Interleukin-4 Receptor.
Permpoon U; Khan F; Vadevoo SMP; Gurung S; Gunassekaran GR; Kim MJ; Kim SH; Thuwajit P; Lee B
Mol Pharm; 2020 Nov; 17(11):4077-4088. PubMed ID: 32881535
[TBL] [Abstract][Full Text] [Related]
4. Tumor-penetrating peptide fused to a pro-apoptotic peptide facilitates effective gastric cancer therapy.
Huang Y; Li X; Sha H; Zhang L; Bian X; Han X; Liu B
Oncol Rep; 2017 Apr; 37(4):2063-2070. PubMed ID: 28260064
[TBL] [Abstract][Full Text] [Related]
5. Selective apoptotic killing of solid and hematologic tumor cells by bombesin-targeted delivery of mitochondria-disrupting peptides.
Cai H; Yang H; Xiang B; Li S; Liu S; Wan L; Zhang J; Li Y; Cheng J; Lu X
Mol Pharm; 2010 Apr; 7(2):586-96. PubMed ID: 20141196
[TBL] [Abstract][Full Text] [Related]
6. Enhanced antitumor effects of the BRBP1 compound peptide BRBP1-TAT-KLA on human brain metastatic breast cancer.
Fu B; Long W; Zhang Y; Zhang A; Miao F; Shen Y; Pan N; Gan G; Nie F; He Y; Zhang J; Teng G
Sci Rep; 2015 Jan; 5():8029. PubMed ID: 25619721
[TBL] [Abstract][Full Text] [Related]
7. Tumor targeting and microenvironment-responsive multifunctional fusion protein for pro-apoptotic peptide delivery.
Yin J; Liu D; Bao L; Wang Q; Chen Y; Hou S; Yue Y; Yao W; Gao X
Cancer Lett; 2019 Jun; 452():38-50. PubMed ID: 30904618
[TBL] [Abstract][Full Text] [Related]
8. A proapoptotic peptide conjugated to penetratin selectively inhibits tumor cell growth.
Alves ID; Carré M; Montero MP; Castano S; Lecomte S; Marquant R; Lecorché P; Burlina F; Schatz C; Sagan S; Chassaing G; Braguer D; Lavielle S
Biochim Biophys Acta; 2014 Aug; 1838(8):2087-98. PubMed ID: 24796502
[TBL] [Abstract][Full Text] [Related]
9. Identification of novel CD44v6-binding peptides that block CD44v6 and deliver a pro-apoptotic peptide to tumors to inhibit tumor growth and metastasis in mice.
Khan F; Gurung S; Gunassekaran GR; Vadevoo SMP; Chi L; Permpoon U; Haque ME; Lee YK; Lee SW; Kim S; Lee B
Theranostics; 2021; 11(3):1326-1344. PubMed ID: 33391537
[TBL] [Abstract][Full Text] [Related]
10. A mitochondrial targeted fusion peptide exhibits remarkable cytotoxicity.
Law B; Quinti L; Choi Y; Weissleder R; Tung CH
Mol Cancer Ther; 2006 Aug; 5(8):1944-9. PubMed ID: 16928814
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and evaluation of multivalent M2pep peptides for targeting alternatively activated M2 macrophages.
Ngambenjawong C; Cieslewicz M; Schellinger JG; Pun SH
J Control Release; 2016 Feb; 224():103-111. PubMed ID: 26772876
[TBL] [Abstract][Full Text] [Related]
12. Nortriptyline induces mitochondria and death receptor-mediated apoptosis in bladder cancer cells and inhibits bladder tumor growth in vivo.
Yuan SY; Cheng CL; Ho HC; Wang SS; Chiu KY; Su CK; Ou YC; Lin CC
Eur J Pharmacol; 2015 Aug; 761():309-20. PubMed ID: 26086857
[TBL] [Abstract][Full Text] [Related]
13. Targeting bladder tumor cells in vivo and in the urine with a peptide identified by phage display.
Lee SM; Lee EJ; Hong HY; Kwon MK; Kwon TH; Choi JY; Park RW; Kwon TG; Yoo ES; Yoon GS; Kim IS; Ruoslahti E; Lee BH
Mol Cancer Res; 2007 Jan; 5(1):11-9. PubMed ID: 17259343
[TBL] [Abstract][Full Text] [Related]
14. A surface charge-switchable and folate modified system for co-delivery of proapoptosis peptide and p53 plasmid in cancer therapy.
Chen S; Rong L; Lei Q; Cao PX; Qin SY; Zheng DW; Jia HZ; Zhu JY; Cheng SX; Zhuo RX; Zhang XZ
Biomaterials; 2016 Jan; 77():149-63. PubMed ID: 26599622
[TBL] [Abstract][Full Text] [Related]
15. Smart pH-Sensitive Nanogels for Enhancing Synergistic Anticancer Effects of Integrin α
Xu Y; Sun L; Feng S; Chen J; Gao Y; Guo L; An X; Nie Y; Zhang Y; Liu X; Ning X
ACS Appl Mater Interfaces; 2019 Sep; 11(38):34663-34675. PubMed ID: 31490654
[TBL] [Abstract][Full Text] [Related]
16. Co-administration of kla-TAT peptide and iRGD to enhance the permeability on A549 3D multiple sphere cells and accumulation on xenograft mice.
Hu C; Chen X; Huang Y; Chen Y
Chem Biol Drug Des; 2018 Aug; 92(2):1567-1575. PubMed ID: 29722179
[TBL] [Abstract][Full Text] [Related]
17. Dual targeting for metastatic breast cancer and tumor neovasculature by EphA2-mediated nanocarriers.
Guo Z; He B; Yuan L; Dai W; Zhang H; Wang X; Wang J; Zhang X; Zhang Q
Int J Pharm; 2015 Sep; 493(1-2):380-9. PubMed ID: 26004003
[TBL] [Abstract][Full Text] [Related]
18. Calcium ionophore, ionomycin inhibits growth of human bladder cancer cells both in vitro and in vivo with alteration of Bcl-2 and Bax expression levels.
Miyake H; Hara I; Yamanaka K; Arakawa S; Kamidono S
J Urol; 1999 Sep; 162(3 Pt 1):916-21. PubMed ID: 10458408
[TBL] [Abstract][Full Text] [Related]
19. Application of Bld-1-Embedded Elastin-Like Polypeptides in Tumor Targeting.
Sarangthem V; Cho EA; Yi A; Kim SK; Lee BH; Park RW
Sci Rep; 2018 Mar; 8(1):3892. PubMed ID: 29497090
[TBL] [Abstract][Full Text] [Related]
20. Effect of combination therapy with a novel bisphosphonate, minodronate (YM529), and docetaxel on a model of bone metastasis by human transitional cell carcinoma.
Inoue K; Karashima T; Fukata S; Nomura A; Kawada C; Kurabayashi A; Furihata M; Ohtsuki Y; Shuin T
Clin Cancer Res; 2005 Sep; 11(18):6669-77. PubMed ID: 16166446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
